NCT00134498

CompletedPhase 3

A Study Comparing The Efficacy & Safety Of Torcetrapib/Atorv...

Pfizer Source

Pfizer

ClinicalTrials.gov

Compare

Other study identifiers

Sponsor study identifier

A5091025

Study Type

interventional

Reported enrollment (type unavailable)

160

Locations

2 countries

Sites

44

Timeline

Study Start

February 2005

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

Not reported

Date not reported

Study Completion

November 2006

Date type not reported

This date has not been verified as actual or estimated.

Brief Summary

The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To assess the safety and efficacy of the fixed combination torcetrapib/atorvastatin in subjects with Fredrickson Type IV Hypertriglyceridemia.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Reported enrollment (type unavailable): 160 participants
Study completion date: November 2006
Date type not reported
This date has not been verified as actual or estimated.
Listed locations: 2 countries · 44 sites

Trial Relationships

Click on a node to explore related trials.

Some registry-reported names shown below are not yet linked in this graph.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
February 2005
Date type not reported
This date has not been verified as actual or estimated.
First Submitted
August 22, 2005
Actual (reported)
First Posted
August 24, 2005
Actual (reported)
Study Completion
November 2006
Date type not reported
This date has not been verified as actual or estimated.

Last Updated: November 16, 2007
Status Verified: March 2007
Last Update Submitted: November 15, 2007

Conditions

Hyperlipoproteinemia Type IV Hypertriglyceridemia

Outcome Measures

Primary Outcomes (1)

Change in HDL-C and non-HDL-C levels

Secondary Outcomes (1)

Changes in levels of other lipid and biomarkers.

Interventions

torcetrapib/atorvastatinDrug

atorvastatinDrug

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Diagnosis of Fredrickson Type IV Hypertriglyceridemia

You may not qualify if:

Sponsors & Collaborators

Pfizer
Industrylead

Study Sites (44)

Pfizer Investigational Site

Anaheim, California, United States

Pfizer Investigational Site

Huntington Beach, California, United States

Pfizer Investigational Site

Los Angeles, California, United States

Pfizer Investigational Site

Orange, California, United States

Pfizer Investigational Site

Orangevale, California, United States

Pfizer Investigational Site

Pacific Palisades, California, United States

Pfizer Investigational Site

Studio City, California, United States

MeSH Terms

Conditions

HypertriglyceridemiaHyperlipoproteinemia Type IV

Interventions

torcetrapibAtorvastatin

Condition Hierarchy (Ancestors)

HyperlipidemiasDyslipidemiasLipid Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesLipid Metabolism, Inborn ErrorsMetabolism, Inborn ErrorsGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesHyperlipoproteinemias

Study Officials

Pfizer CT.gov Call Center
Pfizer
STUDY DIRECTOR

Study Design

Study Type: interventional
Phase: phase 3
Allocation: RANDOMIZED
Masking: DOUBLE
Purpose: TREATMENT
Intervention Model: PARALLEL
Sponsor Type: INDUSTRY

Study Record Dates

First Submitted

August 22, 2005

First Posted

August 24, 2005

Study Start

February 2005

Date type not reported

This date has not been verified as actual or estimated.

Study Completion

November 2006

Date type not reported

NCT00134238

Carotid B-mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrapib/Atorvastatin to Atorvastatin.

Phase 3Terminated

NCT00134173

A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease

Phase 3Completed

NCT00145431

Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Subjects With A Genetic Cholesterol Disorder.

Phase 3Terminated

NCT00136981

Carotid B-Mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrpib/Atorvastatin to Atorvastatin Alone.

Phase 3Completed

NCT00134511

Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Patients With Genetic High Cholesterol Disorder

Phase 3Completed

NCT00435045

Evaluation of Efficacy and Safety of Omacor, Co-Administered With Atorvastatin, in Subjects With Hypertriglyceridemia

Phase 3Completed

Women who are pregnant or lactating, or planning to become pregnant.

Subjects with a clinically indicated need for statin (HMG-CoA reductase inhibitor) therapy other than atorvastatin or other concomitant therapy with known lipid altering effects on LDL-C and HDL-C including fibrates and nicotinic acid

Subjects taking any drugs known to be associated with an increased risk of myositis in combination with HMG-CoA reductase inhibitors

Subjects with any other medical condition or laboratory abnormality which could affect subject safety, preclude evaluation of response, or render unlikely that the subject would complete the study

Contact the study team to confirm eligibility.

Pfizer Investigational Site

Tustin, California, United States

Pfizer Investigational Site

Walnut Creek, California, United States

Pfizer Investigational Site

Farmington, Connecticut, United States

Pfizer Investigational Site

Washington D.C., District of Columbia, United States

Pfizer Investigational Site

Hollywood, Florida, United States

Pfizer Investigational Site

Longwood, Florida, United States

Pfizer Investigational Site

West Palm Beach, Florida, United States

Pfizer Investigational Site

Tripler AMC, Hawaii, United States

Pfizer Investigational Site

Chicago, Illinois, United States

Pfizer Investigational Site

Indianapolis, Indiana, United States

Pfizer Investigational Site

Overland Park, Kansas, United States

Pfizer Investigational Site

Baton Rouge, Louisiana, United States

Pfizer Investigational Site

Scarborough, Maine, United States

Pfizer Investigational Site

Bethesda, Maryland, United States

Pfizer Investigational Site

Ann Arbor, Michigan, United States

Pfizer Investigational Site

Canton, Michigan, United States

Pfizer Investigational Site

Portage, Michigan, United States

Pfizer Investigational Site

Richland, Michigan, United States

Pfizer Investigational Site

Saint Cloud, Minnesota, United States

Pfizer Investigational Site

Olive Branch, Mississippi, United States

Pfizer Investigational Site

Jefferson City, Missouri, United States

Pfizer Investigational Site

St Louis, Missouri, United States

Pfizer Investigational Site

Las Vegas, Nevada, United States

Pfizer Investigational Site

Rochester, New York, United States

Pfizer Investigational Site

Syracuse, New York, United States

Pfizer Investigational Site

West Seneca, New York, United States

Pfizer Investigational Site

Statesville, North Carolina, United States

Pfizer Investigational Site

Sellersville, Pennsylvania, United States

Pfizer Investigational Site

Warwick, Rhode Island, United States

Pfizer Investigational Site

San Antonio, Texas, United States

Pfizer Investigational Site

Richmond, Virginia, United States

Pfizer Investigational Site

Madison, Wisconsin, United States

Pfizer Investigational Site

Halifax, Nova Scotia, Canada

Pfizer Investigational Site

London, Ontario, Canada

Pfizer Investigational Site

Chicoutimi, Quebec, Canada

Pfizer Investigational Site

Montreal, Quebec, Canada

Pfizer Investigational Site

Ste-Foy, Quebec, Canada

Intervention Hierarchy (Ancestors)

PyrrolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsHeptanoic AcidsFatty AcidsLipids

This date has not been verified as actual or estimated.

Last Updated

November 16, 2007

Record last verified: 2007-03

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT00134498
Data provider: ClinicalTrials.gov
Source updated: 2007-11-16
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:32:58 UTC

Locations

CA(5)US(39)

A Study Comparing The Efficacy & Safety Of Torcetrapib/Atorvastatin And Atorvastatin In Subjects With High Triglycerides

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Interventions

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

Study Sites (44)

Related Links

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Officials

Study Design

Study Record Dates

Intervention Hierarchy (Ancestors)

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Interventions

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

Study Sites (44)

Related Links

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Officials

Study Design

Study Record Dates

Intervention Hierarchy (Ancestors)

Source record

Locations